

RayBiotech, Inc.

3607 Parkway Lane suite 200 Norcross,GA 30092 Tel: 770-729-2992, 1-888-494-8555

Fax: 770-206-2393

Website: www.raybiotech.com Email: info@raybiotech.com

Certificate of Analysis and Data Sheet

Mouse Anti-Human IgM, RPE-labeled

Catalog No.Target SpeciesIsotypeDS-MB-03360HumanIgG1

Preparation

Purified IgG prepared by affinity chromatography on Protein A

Fusion Partners: Spleen cells from immunized BALB/c mice were fused with cells of the mouse NS1 myeloma cell line.

Formulation

Product Form: Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized

Product Type: Monoclonal Antibody

Reconstitution: Reconstitute with 1 ml distilled water

Buffer Solution: Phosphate buffered saline

Preservative Stabilizers: 0.09% Sodium Azide, 1% Bovine Serum Albumin

Specificity

This product recognizes human IgM, binding to the m heavy chain. The antibody does not cross-react with other immunoglobulin classes.

Applications

Options Functions	YES	NO	Not determined	Recommended Work dilution or concentration
Flow Cytometry (1)	•			Neat
Immunohistology - Frozen			•	
Western Blotting			•	
Elisa			•	

Note: Other applications have not been tested. Optimal dilutions should be determined.

(1) Use 10ul of the suggested working dilution to label 10⁶ cells in 100ul.



RayBiotech, Inc.

3607 Parkway Lane suite 200 Norcross,GA 30092 Tel: 770-729-2992, 1-888-494-8555

Fax: 770-206-2393

Website: www.raybiotech.com Email: info@raybiotech.com

Storage

Prior to reconstitution store at +4°C. Following reconstitution store at +4°C. This product should be stored undiluted.

DO NOT FREEZE

This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.

Shelf Life: 12 months from date of reconstitution.

References

- 1. Cragg, M.S. *et al.* (1999) Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells. Br. J. Cancer. 79: 850-7.
- 2. Irie, E. *et al.* (2010) Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol. DOI 10.1007/s12185-010-0528-6